Pronai Therapeutics Inc.'s DNA interference (DNAi) technology charmed Wall Street enough to let the company pull off a $137.7 million IPO and end the day with newly traded shares (NASDAQ:DNAI) selling for $30.80, up $13.80, or 81.2 percent.